ReviewNature reviews. Genetics2026
Regulation of gene expression by alternative polyadenylation in health and disease.
Review in Nature reviews. Genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- PABPC1 in Cancer: From a Translational Housekeeper to a Stress-Responsive Regulatory Hub.Cancer science · 2026Review
- ZBP1 in Neuroinflammation and Neurodegeneration: Z-Nucleic-Acid Sensing, RHIM Signalling and Therapeutic Targeting.International journal of molecular sciences · 2026Review
- The alternative polyadenylation factor CFIm25 orchestrates macrophage antibacterial activity againstInfection and immunity · 2026Article
- FABP7: A Regulator of Neuro-Immune Metabolic Networks and Therapeutic Vulnerabilities in Glioma.Cancers · 2026Review
- Nanopore full-length sequencing reveals Nudt21 knockdown drives genome-wide 3'UTR shortening and transcriptome reprogramming in mouse hepatocytes.BMC genomics · 2026Article
- Temporal gating dictates stress-induced transcript export from the nucleus.bioRxiv : the preprint server for biology · 2026Article
- Modulating the cleavage and polyadenylation site: from research tools to therapeutic opportunities.RNA (New York, N.Y.) · 2026Review
- mRNA processing in cancer immunotherapy: emerging targets, resistance mechanisms, and therapeutic opportunities.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
More than half of the human protein-coding genes display alternative polyadenylation (APA), whereby 3'-end processing of the nascent RNA takes place at different sites. APA leads to mRNA isoforms containing different 3' untranslated regions (3'UTRs), which generally modulate mRNA metabolism in cis but can also exert cellular functions in trans. In addition, intronic APA alters protein sequences at the carboxy-terminal region or inhibits gene expression through premature transcription termination. APA is increasingly recognized as a key layer of transcriptomic regulation that defines cell identity and proliferation and/or differentiation states, as well as controlling cellular responses to environmental cues. The relevance of APA for human health is highlighted by the many pathological conditions that are associated with APA dysregulation, including cancer, developmental disorders and neurodegeneration, as well as the disease risks associated with a growing number of genetic variations shown to affect APA. Here, we discuss physiological and pathological APA dynamics, the human mutations and genetic variants that are associated with changes in APA, and our current understanding of the functional effects and regulatory mechanisms of APA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.